sanofi: search

LG Electronics plans for Blu-ray disc player with capability to stream movies from Netflix to TV - Quick Facts

Sanofi-Aventis Q2 Adj. net profit down on lower sales; lifts FY08 earnings growth forecast - Update 1

Cabot Microelectronics gets Ruling in Markman Hearing in Patent litigation against DuPont Air Products NanoMaterials - quick facts

Sanofi-Aventis Q2 Adj. net profit down on lower sales; lifts FY08 earnings growth forecast - Update 1

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Search took 0.01 seconds.